

**Multicorp International Inc.**  
5308 Derry Ave, Suite R, Agoura Hills, Ca 91301  
818-262-6222  
Multicorpinternational.com  
info@multicorpinternational.com

## Annual Report Information Statement

For the year ended December 31, 2023 (the "Reporting Period")

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was: 1,312,387,031 shares as of 12/31/2023

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☒ No: ☐

### **Change in Control**

Indicate by check mark whether a Change in Control of the company has occurred during this reporting period:

Yes: ☐ No: ☒

### **1) Name and address(es) of the issuer and its predecessors (if any)**

Current name of Issuer is MultiCorp International Inc. The Issuer was incorporated on 10/12/2002 under the name of PRIME RATE INVESTORS, INC. Issuer changed its name to SUMMUS WORKS INC. on 02/16/2006. Issuer changed its name to XTEND MEDICAL CORPORATION on 08/28/2007. Issuer changed its name to MultiCorp International Inc. on 04/26/2012.

The issuer is incorporated in Delaware and its status is active.

Neither the issuer nor any predecessor has had any trading suspension or halt orders issued by the SEC or FINRA since inception.

The issuer has not had any stock split, dividend, recapitalization, merger, acquisition, or reorganization within the past 12 months and none are currently anticipated.

The address of the issuer's principal executive office and principal place of business is 5308 Derry Ave, Suite R, Agoura Hills, Ca 91301.

The issuer has not been in bankruptcy, receivership, or any similar proceeding in the past five years.

[Remainder of page left blank.]

## 2) Security Information

### **Transfer Agent**

Name: Signature Stock Transfer, Inc  
Phone: 972-612-4120  
Email: info@signaturestocktransfer.com  
Address: 14673 Midway Road, Suite 220, Addison, Tx 75001

### **Publicly Quoted or Traded Securities:**

Trading symbol:	MCIC
Exact title and class of securities outstanding:	Common Shares
CUSIP:	0001176830
Par or stated value:	\$0.0000001
Total shares authorized:	1,750,000,000 as of date: 12/31/2023
Total shares outstanding:	1,321,387,031 as of date: 12/31/2023
Total number of shareholders of record:	252 as of date: 12/31/2023

### **Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

Exact title and class of the security:	Series A Preferred Stock
Par or stated value:	\$0.0000001
Total shares authorized:	1,000,000 as of 12/31/2023
Total shares outstanding	59,500,000 as of 12/31/2023
Total number of shareholders of record	61 as of 12/31/2023

### **Security Description:**

1. **For common equity, describe any dividend, voting and preemption rights.**

The common stock has one vote per share on all matters presented to the stockholders for approval, the right to receive dividends as, when, and if declared by the board of directors after payment of any dividends payable to holders of preferred stock and the right to receive all assets in liquidation after payment of all debts and payments of preferences to holders of preferred stock.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

The Series A Preferred Stock has ten votes per share (on an as converted basis) on all matters presented to the stockholders for approval voting together as a single class, the right to receive dividends in pari passu with the common stock as, when, and if declared by the board of directors, convertible into common stock on a 10:1 basis, subject to adjustment for for stock dividend on common, splits, reclass, exchange reorganization, merger, consolidation and the right to receive all assets in liquidation after payment of all debts in "an amount equal to \$1.00 in the aggregate for all issued and outstanding shares of Series A Preferred Stock".

3. **Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

None

## 3) **Issuance History**

**A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period**

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years: No: ☒ Yes: ☐

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities: No: ☒ Yes: ☐

### 4) Issuer's Business, Products and Services

#### A. Summary of business operations

The issuer buys and sells nitrile medically approved gloves and other PPE supplies to include gowns, masks and other items for the medical industry. The company is currently working on a medical app that will assist in monitoring potential life threatening scenarios. In addition, the issuer is always looking for cutting-edge technologies and opportunities to increase their ability to bring shareholder value by increasing revenues and profits for the long-term growth of the company.



B. The issuer does not have any subsidiaries, parent company, or affiliated companies.

#### C. The issuers principal products or services

The issuer is a supplier of PPE gloves and is also committed to identifying and acquiring companies that are focused on growth in a variety of medical and technical sectors. We have positioned ourselves to work with global supply chains for the much-needed PPE, medicines, vaccines and pharmacological products that can help patients stay safe and live healthier lives. The key strategy is to keep the costs of our products down with supply chains and to generate sales contracts by identifying networks of customers.

### 5) Issuer's Facilities

The company currently leases offices space at the address stated above. 2000 Square feet, 5 years, \$22,800, CPI rental increases. The company has enough space to operate this business.

### 6) All Officers, Directors, and Control Persons of the company

Names	Title	Residential Address	Shares owned	Type/class	Percentage
Benjamin Friedman	Director, CEO, & President	Agoura Hills, California	659,750,000	Common	50.3%
			59,500,000	Preferred	97.5%

## 7) Legal/Disciplinary History

- A. No person named above has, in the past 10 years, been the subject of:
1. An indictment or conviction in a criminal proceeding or a plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
  2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;
  3. A finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated; or
  4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or
  5. An order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
  6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.
- B. The issuer has no material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject.

## 8) Third Party Service Providers

### Securities Counsel

Name: Jackson L. Morris, Esq  
Address: 126 21<sup>st</sup> Avenue SE, St Petersburg, Florida 33705-2827  
Phone: 813-892-5969  
Email: Jackson.Morris@rule144solution.com

### Accountant

Name: Craig Ainge  
Firm: Ainge CPA group  
Address: 118 N 1600 W, Mapleton, UT 84664  
Phone: 801-489-8099  
Email: parker@aingecpagroup.com

### Investor Relations

None

## 9) Disclosure & Financial Statements

A. This Disclosure Statement was prepared by:

Name: Benjamin Friedman  
Title: CEO  
Relationship with Company: Principal Executive Officer and Principal Financial Officer

B. The following financial statements were prepared in accordance with: ☐ IFRS ☒ U.S. GAAP

C. The following financial statements were prepared by:

Name: Parker Ainge  
Title: Certified Public Accountant  
Relationship with Company: Outside accountant

Index to Financial Statements

- a. Balance Sheet;
- b. Statement of Income;
- c. Statement of Cash Flows;
- d. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- e. Financial Notes

**10) Issuer Certification**

*Principal Executive Officer and Principal Financial Officer:*

I, Benjamin Friedman, certify that:

1. I have reviewed this Annual Disclosure Statement for Multicorp International Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 27, 2024

/s/ Benjamin Friedman

Benjamin Friedman, Principal Executive and Financial Officer,

[Remainder of page left blank.]

**MULTICORP INTERNATIONAL, INC.**

	Page
CONDENSED BALANCE SHEET AS OF DECEMBER 31, 2023 AND DECEMBER 31, 2022 (UNAUDITED)	2
CONDENSED STATEMENT OF OPERATIONS FOR 12 MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED)	3
CONDENSED STATEMENT OF CASH FLOWS FOR THE 12 MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED)	4
CONDENSED STATEMENT OF SHAREHOLDERS' EQUITY FOR THE 12 MONTHS ENDED DECEMBER 31, 2023 (UNAUDITED)	5
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)	6

These financial statements and notes thereto present fairly, in all material respects, the financial position of the company and the results of its operations and cash flows for the period presented, in conformity with accounting principles generally accepted in the United States, consistently applied.

**MULTICORP INTERNATIONAL, INC.**  
**CONDENSED BALANCE SHEET**  
(Unaudited)

	<u>12/31/2023</u>	<u>12/31/2022</u>
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash	\$6,347.66	\$2,153.71
Inventory	\$189,576.64	\$0
<b>TOTAL ASSETS</b>	<b>\$195,924.30</b>	<b>\$2,153.71</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>SHORT TERM LIABILITIES</b>		
Accrued Interest Payable	\$14,069.10	\$3,620.10
<b>LONG TERM LIABILITIES</b>		
Loans from Shareholders-Related Party	\$353,699.89	\$117,899.89
<b>SHAREHOLDERS' EQUITY</b>		
<b>CAPITAL STOCK</b>		
Common Stock, Authorized shares 1,750,000,000 Issues and outstanding – 1,312,387,031 @ PV \$0.0000001	\$131.23	\$131.23
Preferred Stock, Authorized shares 100,000,000 Issued and outstanding – 61,000,000 @ PV \$0.0000001	\$6.10	\$6.10
Additional Paid-in Capital	\$219,478.85	\$219,478.85
<b>ACCUMULATED DEFICIT</b>	(\$391,460.87)	(\$338,982.46)
<b>TOTAL SHAREHOLDERS' DEFICIT</b>	<b>(171,844.69)</b>	<b>(119,366.28)</b>
<b>TOTAL LIABILITIES &amp; STOCKHOLDER'S EQUITY</b>	<b>\$195,924.30</b>	<b>\$2,153.71</b>

**MULTICORP INTERNATIONAL, INC.**  
**CONDENSED STATEMENT OF OPERATIONS**  
**FOR THE 12 MONTHS ENDED DECEMBER 31, 2023 AND DECEMBER 31, 2022**  
**(Unaudited)**

	<b>TWELVE MONTHS ENDED <u>12/31/2023</u></b>	<b>TWELVE MONTHS ENDED <u>12/31/2022</u></b>
<b>Revenue</b>	\$0	\$0
<b>OPERATING EXPENSES</b>		
Bank Service Charges	\$60.00	\$0
Consulting	\$5,000.00	\$0
Software/Website Fees	\$12,913.30	\$4,950.00
Interest	\$7,796.25	\$3,041.94
Listing Fees	\$200.00	\$0
Market Fees	\$0	\$6,092.50
Meals	\$0	\$176.87
Outside Services	\$257.50	\$0
Professional Fees	\$19,736.95	\$34,311.20
Signature Stock	\$1,200.00	\$2,425.00
Storage	\$900.00	\$0
Supplies	\$2,667.93	\$2,735.00
Taxes & Licenses	\$1,419.00	\$26.71
Travel	\$0	\$2,151.79
Web Design	\$327.48	\$3,081.99
<b>TOTAL OPERATING EXPENSES</b>	<b>\$52,478.41</b>	<b>\$58,993.00</b>
<b>NET INCOME/(LOSS)</b>	<b>(\$52,478.41)</b>	<b>(\$58,993.00)</b>



**MULTICORP INTERNATIONAL, INC.**  
**CONDENSED STATEMENT OF CASH FLOWS**  
(Unaudited)

	<u><b>12/31/2023</b></u>	<u><b>12/31/2022</b></u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit/Loss from Operations	(\$52,478.41)	(\$58,992.67)
<b>ADJUSTMENTS TO CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Accrued Interest Payable	\$10,449	(\$3,041.94)
Inventory	(\$189,576.64)	\$0
NET CASH FLOWS FROM OPERATING ACTIVITIES	(\$231,606.05)	(\$55,950.73)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Interest Earned	\$0	\$0
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Additional Paid-in Capital	\$0	\$0
Notes Payable Repayments	\$0	\$0
Proceeds from Stock Sales	\$0	\$0
Loans from Shareholders-Related Party	\$235,800.00	\$49,230.99
NET CASH FLOWS FROM FINANCING ACTIVITIES	\$235,800.00	\$49,230.99
<b>NET INCREASE(DECREASE) IN CASH AND CASH EQUIVALENTS</b>	\$4,193.05	(\$6,719.74)
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b>	\$2,153.71	\$8,873.45
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>\$6,347.66</b>	<b>\$2,153.71</b>

**MULTICORP INTERNATIONAL, INC.**  
**CONDENSED STATEMENT OF SHAREHOLDERS' EQUITY**  
**FOR THE 12 MONTHS ENDED DECEMBER 31, 2023**  
(Unaudited)

	<b>Common Stock</b>	<b>Preferred Stock</b>	<b>Additional Paid-in- Capital</b>	<b>Retained Earnings</b>	<b>Common stock in Treasury</b>	<b>Total</b>
<b>Balance at December 31, 2021</b>	<b>\$131</b>	<b>\$6</b>	<b>\$219,479</b>	<b>(\$279,990)</b>	<b>\$0</b>	<b>(\$60,374)</b>
Common Stock, Par Value, \$.0000001; 1,750,000,000 shares authorized, 1,312,387,031 shares issued/outstanding	-	-	-	-	-	-
Preferred Stock, Par Value, \$.0000001 100,000,000 shares authorized 61,000,000 shares issued/outstanding	-	-	-	-	-	-
Stock Issued	-	-	-	-	-	-
Net Income	-	-	-	(\$58,993)	-	(\$58,993)
Dividends	-	-	-	-	-	-
Reclass Stock	-	-	-	-	-	-
Treasury Stock	-	-	-	-	-	-
<b>Balance at December 31, 2022</b>	<b>\$131</b>	<b>\$6</b>	<b>\$219,479</b>	<b>(\$338,983)</b>	<b>\$0</b>	<b>(\$119,367)</b>
Common Stock, Par Value, \$.0000001; 1,750,000,000 shares authorized, 1,312,387,031 shares issued/outstanding	-	-	-	-	-	-
Preferred Stock, Par Value, \$.0000001 100,000,000 shares authorized 61,000,000 shares issued/outstanding	-	-	-	-	-	-
Stock Issued	-	-	-	-	-	-
Net Income	-	-	-	(\$52,478)	-	(\$52,478)
Dividends	-	-	-	-	-	-
Reclass Stock	-	-	-	-	-	-
Treasury Stock	-	-	-	-	-	-
<b>Balance at December 31, 2023</b>	<b>\$131</b>	<b>\$6</b>	<b>\$219,479</b>	<b>(\$391,462)</b>	<b>\$0</b>	<b>(\$171,846)</b>

**MULTICORP INTERNATIONAL, INC.**  
**NOTES TO CONDENSED FINANCIAL STATEMENTS**  
**FOR THE 12 MONTHS ENDED DECEMBER 31, 2023 & 2022**  
(Unaudited)

**Note 1. ORGANIZATION AND DESCRIPTION OF BUSINESS**

The current name of the issuer is MultiCorp International Inc. The issuer was incorporated on October 12, 2002, under the name Prime Rate Investors, Inc. It changed its name to Summus Works Inc. on February 16, 2006, then to Xtend Medical Corporation on August 28, 2007, and finally to MultiCorp International Inc. on April 26, 2012. The issuer is incorporated in Delaware, and its status is active.

The issuer buys and sells nitrile medically approved gloves and other PPE supplies to include gowns, masks and other items for the medical industry.

**Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES**

**Basis of Presentation**

The financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The financial statements are presented on the accrual basis of accounting. The company has adopted a December 31 year end.

**Use of Estimates**

The preparation of financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Note 3. Cash and Cash Equivalents**

For the purposes of the statement of cash flows, "cash and cash equivalent" represent cash in hand, current bank accounts and fixed deposits with banks maturing within three months or less from the balance sheet date. Over draft bank account fluctuating from debit to credit balance are deducted from "cash and cash equivalent".

**Note 4. Revenue Recognition**

The Company recognized no revenue in the reporting period. The revenue recognition policy complies with ASC 606, which requires revenue to be recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.

**Note 5. Loss from Operations**

The loss from operations is primarily attributed to ongoing operational costs exceeding the Company's revenue, which was \$0 for the year ended December 31, 2023.

**Note 6. Property, Plant, and Equipment**

Property, plant, and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets.

**Note 7. Leases**

The Company follows ASC 842 for lease accounting, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for lease terms of more than 12 months.

**Note 8. Trade Accounts Receivables**

Accounts receivable are shown on the balance sheet at their net realizable value. A provision for doubtful accounts is taken after reviewing all the balances at year end. Uncollected amounts are written off in the period they are recognized. The company currently does not have any open receivables.

**Note 9. Financial Instruments**

A financial instrument is any contract that gives rise to both a financial asset of one enterprise and a financial liability or equity instrument of another enterprise. The company's financial instruments principally comprise of cash and bank balances, accounts receivable, accounts payable, accrued expenses and short-term borrowings.

**Note 10. Income Taxes**

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.

**Note 11. Commitments and Contingencies**

The Company discloses significant commitments and potential contingencies, including legal proceedings and environmental liabilities, if any.

**Note 12. Subsequent Events**

Subsequent events have been evaluated through the date of the report that the financial statements were available to be issued.

**Note 13. Shareholder Loan-Related Party**

A loan was provided to the company by major shareholder Ben Friedman at an interest rate of 3%.